EMA Authorised: Elebrato Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorized Elebrato Ellipta, a fixed-dose inhaled triple therapy for chronic obstructive pulmonary disease comprising fluticasone furoate, umeclidinium brom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Elebrato Ellipta
• Fluticasone Furoate (fluticasone furoate)
• Umeclidinium bromide (umeclidinium bromide)
• vilanterol trifenatate (vilanterol trifenatate)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 31/08/2023